![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 2
Zeitschriftenartikel
Smeitink, Jan; Es, Just van; Bosman, Brigitte; Janssen, Mirian C. H.; Klopstock, Thomas 
ORCID: https://orcid.org/0000-0003-2805-4652; Gorman, Grainne; Vissing, John; Ruiterkamp, Gerrit; Edgar, Chris J.; Abbink, Evertine J.; Maanen, Rob van; Pogoryelova, Oksana; Stendel, Claudia; Bischoff, Almut; Karin, Ivan; Munshi, Mahtab; Kümmel, Anne; Burgert, Lydia; Verhaak, Christianne und Renkema, Herma
(2025):
Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation.
In: Brain, Bd. 148, Nr. 3: S. 896-907
[PDF, 904kB]
ORCID: https://orcid.org/0000-0003-2805-4652; Gorman, Grainne; Vissing, John; Ruiterkamp, Gerrit; Edgar, Chris J.; Abbink, Evertine J.; Maanen, Rob van; Pogoryelova, Oksana; Stendel, Claudia; Bischoff, Almut; Karin, Ivan; Munshi, Mahtab; Kümmel, Anne; Burgert, Lydia; Verhaak, Christianne und Renkema, Herma
(2025):
Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation.
In: Brain, Bd. 148, Nr. 3: S. 896-907
[PDF, 904kB]
Gratzke, Christian; Maanen, Rob van; Chapple, Christopher; Abrams, Paul; Herschorn, Sender; Robinson, Dudley; Ridder, Arwin; Stoelzel, Matthias; Paireddy, Asha; Yoon, Sang Jin; Al-Shukri, Salman; Rechberger, Tomasz und Müller, Elizabeth R.
(2018):
Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
In: European Urology, Bd. 74, Nr. 4: S. 501-509